← headlines

Researchers from thymia and RMIT University developed an AI tool that screens for type 2 diabetes in seconds by analyzing vocal patterns

Business – 19 outlets

Bloomberg

Boehringer, Zealand Obesity Drug’s 13% Weight Loss Disappoints

Lilly Drug Combo Spurs Record Weight Loss in Diabetes Study Opens in new window seen

Lilly Drug Combo Spurs Record Weight Loss in Diabetes Study

CNBC

Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Daily Mail

New test could screen for type 2 diabetes in seconds using just speech, study shows

Irish Independent

New drug combination shows significant weight loss in obesity and type 2 diabetes trial

NBC News

People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug

Quartz

Eli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster

Eli Lilly's experimental weight loss drug shed 21% of body weight in diabetes trial

The Independent

Breakthrough weight-loss drug helps diabetes patients lose a quarter of their body weight

New weight loss drug Retatrutide leads to dramatic results in trials

Fresh hope for diabetics as new weight loss drug helps them shed a quarter of their bodyweight

New AI test can diagnose diabetes in seconds by spotting these two vocal symptoms

How AI could help screen for type 2 diabetes in seconds

USA Today

Forget Zepbound, people on this Lilly drug lost even more weight seen

Financial Post

Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

Forbes

AI Voice Test Could Screen For Type 2 Diabetes, Research Finds

MarketWatch

Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.

NBC Chicago

People with Type 2 diabetes lost up to 60 pounds on Lilly's latest weight loss drug

Newsweek

Type 2 Diabetes Linked to Higher Cancer Rates, Study Finds seen

Phys.org

New investigational drug delivers up to 23.3% weight loss in people with obesity and diabetes seen

Scientific American

Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs

STAT

STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial

The i Paper

How AI could help screen for type 2 diabetes seen

TIME

Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results

WSB-TV

Retatrutide: New drug shows weight loss promise